Saturday 17 October 2026
Export ADVB’s income statement to Excel — free account
Advanced Biomed Inc.
ADVB Healthcare Diagnostics & Research
Advanced Biomed Inc.’s revenue for fiscal 2026 (year ended June 2026) was $127,600.00. In the quarter to June 2026, EPS grew 54.8% and free cash flow fell 101.3%, each against the same quarter a year earlier.
3.98
0.90
−18.44%
Follow ADVB
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+7 more TTM periods Free account |
(144.85%) | 86.84% | 79.17% | 84.77% | |
| (108.29%) | 57.12% | 55.78% | 36.47% | ||
ROIC |
(196.06%) | (10.97%) | (10.97%) | (33.43%) | |
Return on Tangible Assets |
(109.74%) | 45.80% | 57.47% | 54.39% | |
Free Cash Flow per Share |
(5.93) | (5.65) | (2.29) | (3.61) | |
Free Cash Flow |
(6.42) | (6.11) | (2.94) | (4.53) | |
Capital Expenditures |
(0.01) | (0.04) | (0.04) | (2.58) | |
| Other line items | |||||
Cash ROIC |
(113.40%) | (50.59%) | (24.92%) | (35.77%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | — | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
1.90 | (1.39) | (0.55) | (0.29) | |
Depreciation/Fixed assets |
1.03 | 3.43 | 3.67 | — | |
Capex/Depreciation |
(0.05) | (0.11) | (0.11) | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(5.92) | (5.62) | (2.26) | (1.55) | |
Capex per Share |
(0.01) | (0.03) | (0.03) | (2.06) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 15 Oct 2026